Le Lézard
Classified in: Health, Science and technology
Subjects: CHI, SVY

Children's Brain Tumor Network Introduces New "CBTN Champions" Giving Tier to Broaden Support for Researchers and Kids


PHILADELPHIA, May 9, 2024 /PRNewswire/ -- The Children's Brain Tumor Network (CBTN), a global leader in pediatric brain tumor research, shares its latest philanthropic initiative: the CBTN "Champions" tier. With an annual giving threshold of $10,000, this new level aims to engage a broader community of supporters in advancing the CBTN mission of transforming the landscape of childhood brain cancer.

This new giving level engages a broader community of supporters to transform the landscape of childhood brain cancer.

CBTN values the input and collaboration of patient foundations, recognizing their vital roles in driving progress. Relationships with these foundations extend beyond philanthropic giving; they represent partnerships built on shared goals and a commitment to keep patients at the center of research. From its inception, patient families have been the driving force behind CBTN, demanding collaboration and innovation. With the Champions level, CBTN aims to further empower patient foundations of all sizes, ensuring they have the resources and knowledge to advocate effectively for research progress.

Every dollar raised for CBTN is instrumental in collecting data for researchers, providing resources to the research community, advocating for further funds, and ultimately improving outcomes for kids with brain tumor diagnoses.

The CBTN Champions tier provides an accessible opportunity for individuals and organizations to actively participate in the CBTN mission. And more partners mean more progress. This tier complements our existing "Executive Council," composed of generous donors who contribute $25,000 or more annually to ensure that supporters of all levels can play a meaningful role in advancing our cause.

"Our Executive Council members and Champions are at the forefront of our vision to transform the landscape of pediatric brain tumor research," explains Gerri Trooskin, CBTN Director of Partnerships. "Their generosity and commitment empower us to push boundaries, foster innovation, and make a difference for families worldwide."

About Children's Brain Tumor Network (CBTN)
Children's Brain Tumor Network (CBTN) is a collaborative research enterprise with the aim to accelerate treatments to accelerate treatments for children with brain tumors. Collectively, the 35 international member institutions comprising CBTN have enrolled more than 5,000 study participants and more than 70,000 biospecimen samples to create the world's most comprehensive repository of childhood brain tumors. The CBTN suite of cloud-based informatics and analytics platforms enables researchers to collaborate in real-time on behalf of children diagnosed with a brain tumor. To learn more about becoming a CBTN Champion, please visit the CBTN partnerships web page.

Emily Reed
[email protected]
239-240-4248

SOURCE Children's Brain Tumor Network


These press releases may also interest you

at 04:45
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....



News published on and distributed by: